Related Experiment Video

Updated: Jul 11, 2025

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.8K

Serum Levels of Hcy, sST2 and CA-125 in CHF Patients and Their Correlation with Cardiac Function Classification

Wuzhi Ma1, Peng Zhang2, Huiqiong Hu3

  • 1Department of Cardiology, Nanning 10th People's Hospital, 530105 Nanning, Guangxi, China. qianguimice20xcf@163.com.

The Heart Surgery Forum
|November 3, 2023
PubMed

Insights

Elevated homocysteine (Hcy), soluble stromelysin 2 (sST2), and cancer antigen 125 (CA-125) indicate heart failure. Combining these biomarkers offers the best diagnostic value for congestive heart failure (CHF).

Area of Science:

  • Cardiology
  • Biomarker Research
  • Clinical Diagnostics

Background:

  • Investigating the link between serum homocysteine (Hcy), soluble stromelysin 2 (sST2), and cancer antigen 125 (CA-125) and heart failure is crucial.
  • Understanding these biomarker levels can aid in the clinical diagnosis and treatment of heart failure.

Purpose of the Study:

  • To evaluate serum levels of Hcy, sST2, and CA-125 in patients with congestive heart failure (CHF).
  • To correlate these biomarker levels with cardiac function and classification.
  • To assess the diagnostic value of individual and combined biomarkers for CHF.

Main Methods:

  • Seventy patients with chronic heart failure (CHF) (NYHA classes II-IV) and seventy healthy controls were enrolled.
  • Serum levels of Hcy, sST2, and CA-125 were measured in all participants.
  • Biomarker levels were correlated with cardiac function and diagnostic value was assessed individually and in combination.

Main Results:

  • Serum Hcy, sST2, and CA-125 levels were significantly lower in healthy individuals compared to CHF patients.
  • A progressive increase in Hcy, sST2, and CA-125 levels was observed across CHF severity classes (II, III, IV).
  • All three biomarkers, individually and combined, showed significant correlation with cardiac function and demonstrated diagnostic value for CHF, with the combination yielding the highest diagnostic accuracy.

Conclusions:

  • Elevated serum levels of Hcy, sST2, and CA-125 are characteristic of CHF and correlate positively with disease severity.
  • These biomarkers, especially when used in combination, exhibit good sensitivity and specificity for diagnosing CHF.
  • The combined assessment of Hcy, sST2, and CA-125 holds potential for widespread clinical application in heart failure diagnosis.
Abstract

More Related Videos

Author Spotlight: Advancing Cardiovascular Imaging - Introducing the Spatially Weighted Calcium Score for Early Disease Detection06:57

Author Spotlight: Advancing Cardiovascular Imaging - Introducing the Spatially Weighted Calcium Score for Early Disease Detection

Published on: September 22, 2023

1.0K
Ultrasonic Assessment of Myocardial Microstructure10:53

Ultrasonic Assessment of Myocardial Microstructure

Published on: January 14, 2014

5.5K

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
98
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
17
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
15
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
18
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
9
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
37